Disease Domain | Count |
---|---|
Neoplasms | 20 |
Endocrinology and Metabolic Disease | 3 |
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Unknown | 3 |
Chemical drugs | 1 |
Target |
Mechanism SHP2 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EIF4EBP1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Ras inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Apr 2024 |
Sponsor / Collaborator |
Start Date18 Jan 2024 |
Sponsor / Collaborator |
Start Date14 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
RMC-4630 ( SHP2 ) | Non-Small Cell Lung Cancer More | Phase 2 |
RMC-6291 ( KRAS G12C x NRAS G12C ) | KRAS G12C mutation Solid Tumors More | Phase 1 |
RMC-6236 ( Ras ) | Non-Small Cell Lung Cancer More | Phase 1 |
RMC-5552 ( mTORC1 ) | Solid tumor More | Phase 1 |
RMC-9805 ( KRAS G12D ) | KRAS G12D mutation Solid Tumors More | Phase 1 |